Sydbank A/S share buyback programme: transactions in week 22
Peberlyk 46200 AabenraaDenmarkTel +45 74 37 37 37Fax +45 74 37 35 36Sydbank A/SCVR No DK 12626509, Aabenraasydbank.dk
1 June 2025
Dear Sirs
Sydbank A/S share buyback programme: transactions in week 22On 26 February 2025 Sydbank A/S announced a share buyback programme of DKK 1,350m. The share buyback programme commenced on 3 March 2025 and will be completed by 31 January 2026.
The purpose of the share buyback programme is to reduce the share capital of Sydbank A/S and the programme is executed in compliance with the provisions of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 and Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016, collectively referred to as the Safe Harbour rules.
The following transactions have been made under the share buyback programme:
Number of shares
VWAP
Gross value (DKK)
Accumulated, most recent Announcement
895,000
374,860,860.00
26 May 202527 May 202528 May 202529 May 2025 (public holiday)30 May 2025 (bankholiday)
14,00012,00012,000--
445.69442.08440.24--
6,239,660.005,304,960.005,282,880.00--
Total over week 22
38,000
16,827,500.00
Total accumulated during theshare buyback programme
933,000
391,688,360.00
All transactions were made under ISIN DK 0010311471 and effected by Danske Bank A/S on behalf of Sydbank A/S.
Further information about the transactions, cf Article 5 of Regulation (EU) No 596/2014 of the European Parliament and of the Council on market abuse and Commission delegated regulation, is available in the attachment.Following the above transactions, Sydbank A/S holds a total of 938,074 own shares, equal to 1.83% of the Bank's share capital. Yours sincerely Mark Luscombe Jørn Adam MøllerCEO Deputy Group Chief Executive
Attachment
SM 25 UK incl. enc
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
HSBC Raises Novo Nordisk (NVO) Price Target on Oral Semaglutide Market Share Boost
Novo Nordisk A/S (NYSE:NVO) is one of the best falling stocks to buy now. On August 7, HSBC maintained a 'Hold' rating on Novo Nordisk and lifted the price target to 355 Danish Krone (DKK) from DKK340. HSBC increased the price target because it raised its estimates for the market share of oral semaglutide. Semaglutide is a pill that helps people with type 2 diabetes or obesity manage their condition. Novo Nordisk sells oral semaglutide for diabetes under the brand name Rybelsus. Pixabay/Public Domain HSBC projects that peak sales for the drug could exceed DKK15 billion ($2.34 billion) after 2034. The bank kept the 'Hold' rating on the stock due to 'ongoing concerns about market size' and 'overhang compounders.' The analysts identified a potential 'upside' for the stock if there is a recovery in Wegovy prescriptions in the U.S. Novo Nordisk A/S (NYSE:NVO) is a Danish global healthcare company. It develops and manufactures pharmaceutical products for chronic diseases, with a primary focus on diabetes, obesity, and rare blood and endocrine disorders. The company's portfolio includes GLP-1 therapies, such as Ozempic and Wegovy, as well as insulin and growth hormone treatments. While we acknowledge the potential of NVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 12 Best Copper Stocks to Buy According to Hedge Funds and 10 Best EV Penny Stocks to Buy According to Hedge Funds. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
24 minutes ago
- Yahoo
Major companies reframing, not abandoning, DEI: report
This story was originally published on ESG Dive. To receive daily news and insights, subscribe to our free daily ESG Dive newsletter. Dive Brief: More than half of S&P 100 companies adjusted how they communicated diversity, equity and inclusion efforts in their annual securities filings this year compared to 2024, according to a new report by The Conference Board. Among S&P 500 companies, the use of the acronym 'DEI' dropped by 68% compared to 2024, according to the report. Twenty-one percent of companies reduced or removed DEI-related metrics and targets. While firms scaled back DEI language and commitments, 79% percent of S&P 500 firms disclosed board committee oversight of DEI, up from 72%, according to the report. For Russell 3000 companies, this figure jumped from 48.4% to 86.8%. Rather than simply abandoning DEI, this suggests that companies are being more cautious about external messaging while integrating DEI into governance to make it more legally defensible, according to the report. Dive Insight: Companies have been rolling back their DEI programs since the Supreme Court's 2023 decision outlawing affirmative action in higher education. After President Donald Trump's reelection, McDonald's, Meta, a few banks and others preemptively adjusted policies in anticipation of backlash. When a January 2025 executive order directed heads of agencies to target private sector DEI, another wave of major companies — including Target, BlackRock and even law firms — dropped their DEI goals, a trend that continues. A July 23 report by reported that 20% of companies have scrapped their DEI programs since Trump's reelection. The Conference Board report, based on 2025 Form-10K filings, largely aligns with the individual headlines. More companies in 2025 have limited disclosures of workforce or leadership diversity. The share of S&P 500 companies that disclosed data on women in management dropped from 71.2% in 2024 to 55.1% in 2025, and the share that disclosed the total number of female board members dropped from 90.5% to 60.4%. Just 2.5% of companies did not disclose any information about board racial diversity in 2024, but that number jumped to 33.9% this year. Among Russell 3000 companies, that figure leaped from 14.1% to 54.7%. In recent years, some U.S. public companies have linked executive compensation to DEI-related goals. In 2024, 68% of S&P 500 companies and 41.6% of Russell 3000 companies disclosed in their annual reports that they linked these metrics. In 2025, this figure dropped to 35.3% for S&P 500 companies and 18.7% for Russell 3000 companies. Instead, in 2025 more companies disclosed how executive compensation was linked to broader human capital goals, such as talent development and employee engagement. 'This shift in public disclosure doesn't signal companies are abandoning DEI,' said Andrew Jones, principal researcher at The Conference Board and coauthor of the report, in an Aug. 4 press release. 'Rather, they're selectively reframing commitments, reducing public exposure and embedding oversight more quietly yet firmly into governance and human capital management.' But as companies shift their DEI strategies to protect themselves in a hostile U.S. legal landscape, they also become increasingly misaligned with international disclosure standards, such as the European Union's Corporate Sustainability Reporting Directive, the International Sustainability Standards Board and the Global Reporting Initiative, the report noted. Such standards still emphasize workforce DEI and generally require more consistent demographic disclosure, the report said. Recommended Reading 1 in 5 companies say they've slashed DEI since Trump's election Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
44 minutes ago
- Yahoo
Piper Sandler Raises IDEXX Laboratories (IDXX) PT to $700, Cites Strong Q2 Results
IDEXX Laboratories Inc. (NASDAQ:IDXX) is one of the best performing S&P 500 stocks to buy now. On August 11, Piper Sandler raised the firm's price target on Idexx Laboratories to $700 from $510 following the company's Q2 2025 financial results. The firm kept a Neutral rating on the shares. IDEXX Laboratories reported total revenues of $1,109 million in Q2, which was an increase of 11% as reported and 9% organically, compared to the prior year. This was driven by a strong performance from its Companion Animal Group/CAG and Water segments, which saw revenue increases of 11% and 9% as reported, respectively. A veterinarian in a veterinary clinic examining a companion animal. Within the Companion Animal Group, IDEXX VetLab consumables revenue grew by 15% as reported and 14% organically. The company also saw a 66% reported increase in CAG Diagnostics capital instrument revenues, driven by record placements of its new IDEXX InVue Dx instrument. Rapid assay products revenues, however, declined by 3% as both reported and organic, as some testing shifted to new modalities. IDEXX Laboratories Inc. (NASDAQ:IDXX) develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the US and internationally. While we acknowledge the potential of IDXX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
